| Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) |
Ongoing |
Carglumic acid |
3 |
IIT-OE-2013-001 |
NGHA-R |
| Phase III, Single-arm, Open-label, International, Multi-centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients with Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid-lowering Therapy |
Ongoing |
LOMITAPIDE |
3 |
APH-19 |
King Abdulaziz Medical City NG (Riyadh) |
| Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age) |
Completed |
Meningococcal ACWY Conjugate Vaccine |
3b |
107402 |
NGHA-R |
| Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients. |
Ongoing |
Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL |
2 |
IRB#17-329 version2 |
KAMC |
| Phase II study of the efficacy of metronomic capecitabine chemotherapy as a maintenance treatment in advanced triple negative breast cancer |
Ongoing |
Capecitabine |
2 |
20-611 |
King Abdullah Medical City (Makkah) |
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Non-Hodgkin’s Lymphoma (NHL) using a Closed Transduction System |
Completed |
CD19-CART |
1, 2 |
2191301 |
KFSH&RC-R |
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) using a Closed Transduction System |
Completed |
CD19-CART |
1/2 |
2191207 |
KFSH&RC-R |
| Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) |
Ongoing |
PF-07055480 (formerly SB-525) |
3 |
C3731003 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) |
Ongoing |
PF-06838435 |
3 |
C0371002 |
KFSH&RC-R |
| "Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS" |
Completed |
Dantrolene |
2 |
EGL-4104-C-1502 |
KFMC |
